Cell and Gene Therapy

TLA based targeted complete next generation sequencing of integrated vectors / transgenes, integration sites and of gene editing events empowers the development and quality control of gene therapy and cell therapy products.


TLA analysis can be applied in different stages during development and application of gene therapy technology:


Characterisation of the producer cell lines


  • Identify the integration site(s);
  • Study structural rearrangements in the host genome;
  • Evaluate if targeting went correctly (e.g. no concatemerisation, no off-target integrations);
  • Characterise the vector/transgene sequence - SNPs and structural variants (e.g. deletions TG-TG fusions);


Evaluation of the transfected/transduced heterogenous cell samples


This means patient/donor-derived cellular gene therapy products, e.g. T-cells and B-cells:


  • Identification of the integration sites (e.g. characterisation of unique integration sites, preference of specific integration sites);
  • Stability of the used vector (e.g. presence of SNPs and structural variants).


TLA is a very powerful tool to quality control genetically engineered cell lines used in the production of gene therapy products and to assess the genetic alterations resulting from the use of gene therapy products.




Watch a replay of a recent webinar on TLA-based targeted transgene & integration site sequencing in gene therapy products.






© 2012-2019 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.
We use cookies for website analysis and marketing. By visiting and using our website you accept these cookies.